This is an automatically translated article.
What is Paclihope? Paclihope is used to treat breast cancer, ovarian cancer, non-small cell lung cancer, and AIDS-related Kaposi melanoma. The cancer drug Paclihope can be used alone or in combination with other drugs to treat metastatic, advanced, or recurrent cancer.
1. Uses of Paclihope
Paclihope belongs to the group of anti-cancer drugs and affects the immune system, the main ingredient is Paclitaxel 30mg. Paclitaxel has anti-cancer effects and modulates the response of the immune system, preventing cells from growing.
Paclihope is prepared as a concentrated solution for intravenous infusion and packaged in 5ml vials. The drug is indicated for use in the following cases:
Treatment of metastatic ovarian cancer in cases where the patient has failed conventional treatments with anthracycline and platinum or is contraindicated to use these two drugs. Co-administration of paclihope with doxorubicin for the adjuvant treatment of metastatic breast cancer in patients who have failed conventional anthracycline treatments or whose breast cancer has recurred within 6 months of adjuvant therapy. Treatment of AIDS-related non-small cell lung cancer and Kaposi's cancer.
2. How to use and dose Paclihope
Cancer drug Paclihope is used by intravenous infusion, medical staff or doctors who perform infusion techniques for patients. Note, before taking the drug, the patient should be treated with H2 receptor blockers, antihistamines and corticosteroids.
Dosage of the cancer drug Paclihope depends on the volume and nature of the tumor, the patient's ability to stand and the patient's response to previously applied platinum chemotherapy.
Dosage of Paclihope in the treatment of ovarian cancer is as follows:
First line regimen - Treatment of advanced epithelial ovarian cancer: Intravenous infusion of 175mg/m2 body surface area over 3 hours, followed inject Cisplatin 75mg/m2; Alternatively, an intravenous infusion of Paclihope 135 mg/m2 over a 24-hour period may be used, followed by an injection of Cisplatin 75 mg/m2. Do it every 3 weeks. Second line regimen - Continuity of treatment for advanced ovarian cancer: Paclihope only intravenous infusion 175mg/m2 for 3 hours. Do it every 3 weeks. Dosage of Paclihope in the treatment of breast cancer is as follows:
Adjuvant treatment: After treatment with AC, intravenous infusion of 175mg/m2 body surface area over 3 hours, injection every 3 weeks and administered show 4 times. First-line regimen - Adjuvant treatment of breast cancer with lymph nodes: Doxorubicin 50mg/m2 injection for 24 hours, then Paclihope 220mg/m2 intravenous infusion for 3 hours, treatment every 3 weeks. Second line regimen - Treatment of metastatic or recurrent breast cancer: Intravenous infusion of 175mg/m2 for 3 hours, treatment every 3 weeks. Dosage of the cancer drug Paclihope in the treatment of malignant non-small cell lung cancer: Intravenous infusion of 175mg/m2 body surface area over 3 hours, followed by Cisplatin injection 80mg/m2, treatment every 3 weeks .
Dosage of Paclihope in the treatment of AIDS-related Kaposi tumors: Intravenous infusion of 100mg/m2 body surface area over 3 hours, treatment every 2 weeks.
3. Side effects of the drug Paclihope
Treatment with Paclihope may cause some unwanted side effects as follows:
Blood vessels: Anemia, thrombocytopenia, leukocytes, neutrophils, spinal cord suppression, hypotension, heart rate slow. Nervous: Neurotoxic (peripheral neuropathy). Gastrointestinal: Paclihope may cause gastrointestinal side effects such as loss of appetite, nausea, vomiting, mucositis, diarrhea. Musculoskeletal: Muscle pain, joint pain. Other: Injection site reactions, infections, hypersensitivity (mild) reactions, alopecia.
4. Some notes when using Paclihope
Do not use Paclihope cancer drug in people with hypersensitivity to the drug's ingredients, people with a neutrophil count less than 1,500/mm3 or obvious signs of motor neuron disease, pregnant women or breastfeeding, children under 18 years of age (as safety and efficacy have not been established). In patients with hepatic impairment or liver dysfunction, the dose of Paclihope should be reduced. Do not use when transaminase levels are 10 times higher than normal or bilirubin levels are above 7.5mg/100ml or 5 times higher than normal. Paclihope should be used with caution in cardiac patients. Prophylactic treatment of hypersensitivity before and after treatment with Paclihope because the drug can cause anaphylactic reactions. People with a history of peripheral neuropathy should use caution when using Paclihope. Platinum derivatives should be used prior to administration of Paclihope or taxane derivatives in cases where multiple administration of drugs is required to reduce the risk of myelosuppression. Elderly people taking Paclihope have a higher risk of neurotoxicity, agranulocytosis. The cancer drug Paclihope may interact with drugs that inhibit or induce CYP2C8 or 3A4, proteases. Therefore, caution should be exercised when taking these drugs together. The use of the drug Paclihope is to affect the immune system and prevent cancer cells from growing. With this use, Paclihope is used alone or in combination with other drugs in the treatment of cancer.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
